Verily Health Launches AI-Powered App to Demystify Medical Jargon

Verily Health has introduced its new AI-powered app, Verily Me, aimed at simplifying complex medical terminology for patients. The launch is accompanied by a marketing campaign featuring two 30-second advertisements that are being broadcasted across national television, audio platforms, and social media channels. This initiative is significant as it addresses the common challenge many patients face in understanding medical jargon, which can lead to confusion and anxiety regarding their health conditions. By leveraging artificial intelligence, Verily Me seeks to provide users with clear explanations and insights into their medical information, thereby enhancing patient engagement and empowerment. The campaign is expected to reach a wide audience, potentially impacting millions of individuals who struggle with health literacy. As the healthcare landscape increasingly incorporates technology, tools like Verily Me could play a crucial role in bridging the communication gap between healthcare providers and patients, fostering better health outcomes.

AI in healthcare / patient engagement / health literacy / digital health / Verily Health

April 2026

Today

Latest Today

Pharma & Medications

BIO Launches 'Fight of Our Lives' Campaign to Celebrate 50 Years of Biotech Innovation

The Biotechnology Innovation Organization (BIO) has initiated a nationwide campaign titled 'The Fight of Our Lives' to commemorate the 50th anniversary of the biotechnology industry. This campaign aims to highlight the transformative stories behind biotech breakthroughs and their significant impact on patient care. Through a series of videos and educational materials, BIO seeks to engage the public and healthcare professionals alike, showcasing how biotechnological advancements have improved health outcomes and saved lives. This initiative is particularly important as it underscores the critical role that biotechnology plays in addressing various health challenges, including chronic diseases and rare conditions. By sharing personal stories of patients who have benefited from biotech innovations, the campaign aims to foster a deeper understanding of the industry's contributions to modern medicine. The campaign not only celebrates past achievements but also emphasizes the ongoing need for innovation in the face of emerging health threats. As the industry looks to the future, BIO's efforts will likely encourage continued investment and support for biotech research and development, ensuring that new therapies and treatments remain at the forefront of healthcare. As the campaign unfolds, it will be crucial for stakeholders in the healthcare sector to engage with the materials and narratives presented, as they reflect the real-world implications of biotechnological advancements on patient lives. The success of this campaign could influence public perception and policy decisions regarding biotechnology in the coming years.

Fierce Pharma

Pharma & Medications

Astellas Shuts Stem Cell Therapy Site; GSK Advances ADC Trials; Daiichi Sells Consumer Health Unit

Astellas Pharma has announced the closure of its stem cell therapy site, a strategic move that reflects the company's reevaluation of its focus in regenerative medicine. This decision may impact ongoing research and development efforts in stem cell therapies, which have been a significant area of interest in recent years. The closure raises questions about the future of such therapies and their potential applications in treating various conditions. In a contrasting development, GlaxoSmithKline (GSK) is intensifying its efforts in the oncology space by advancing a partnered antibody-drug conjugate (ADC) with Hansoh Pharma into multiple phase 3 clinical trials. This initiative underscores GSK's commitment to expanding its oncology portfolio and could lead to new treatment options for patients with cancer, pending successful trial outcomes. Additionally, Daiichi Sankyo is divesting its consumer health business unit for approximately $1.55 billion. This sale indicates a strategic shift for the company, allowing it to concentrate resources on its core pharmaceutical operations. The divestiture may affect the consumer health market landscape, as Daiichi's products transition to new ownership. These developments highlight significant shifts within major pharmaceutical companies, reflecting broader trends in the industry towards specialization and strategic realignment. Stakeholders in the healthcare sector will be closely monitoring these changes as they unfold, particularly in the context of ongoing clinical trials and market dynamics.

Fierce Pharma

Pharma & Medications

All →

Verily Health Launches AI-Powered App to Demystify Medical Jargon

Pharma & Medications